Clinuvel Pharmaceuticals Ltd
NASDAQ:CUVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
NASDAQ:CUVL
|
AU |
|
V
|
Victorian Plumbing Group PLC
F:637
|
UK |
|
R
|
Robogroup TEK Ltd
OTC:ROBOF
|
IL |
|
L
|
Loungers PLC
SWB:LP0
|
UK |
|
B
|
Beijing Enterprises Holdings Ltd
XMUN:BJEB
|
HK |
|
O
|
Oxford Biodynamics PLC
OTC:OXBOF
|
UK |
|
V
|
Vivo Energy PLC
F:7VE
|
UK |
|
T
|
Tianjin Development Holdings Ltd
XMUN:TJN
|
HK |
Wall St Price Targets
CUVL Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CUVL is 13.58 USD with a low forecast of 6.21 USD and a high forecast of 27.65 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CUVL's stock price target?
Price Target
13.58
USD
According to Wall Street analysts, the average 1-year price target for CUVL is 13.58 USD with a low forecast of 6.21 USD and a high forecast of 27.65 USD.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
